Biotech company 3SBIO, which delisted from the Nasdaq two years ago, on Wednesday launched an up to $712 million IPO in Hong Kong to fund acquisitions and recruit staff to help it grab a bigger piece of the booming Chinese drug market. The company, which produces drugs to treat bleeding disorders, hopes to benefit from greater liquidity by listing in Hong Kong alongside other firms which are targeting the Chinese biopharmaceutical market's double-digit growth.